Neurologic Disorders Resource Center
Click on the subcategory below to find drug monographs for that particular area.
Top News
Alzheimer's Rate Falling in the U.S.
Restoring Memory via Implants
Cataract Surgery and Dementia Patients
Parkinsonism, ADHD: Genetic Link?
Advancement in Blood Test for Alzheimer's
Sports Concussions: Ethical, Legal Issues
Wearable Exoskeleton for Paraplegia
Chart: Multiple Sclerosis Treatments
Videos
Clinical Charts
Make prescribing decisions with our comparative charts and treatment algorithms.
Patient Information Fact Sheets
Download or print easy-to-read disease leaflets for your patients.
News
Could Mild TBI Symptoms Be PTSD?
Persistent symptoms lasting three months after mild traumatic brain injury (mTBI) do not represent postconcussion syndrome (PCS) and should be considered part of the hyperarousal dimension of posttraumatic stress disorder.
Status Epilepticus Therapy Granted Fast Track Status
The FDA has designated Fast Track status to SAGE-547 (SAGE Therapeutics) for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens.
Mislabeling Causes Ibuprofen, Oxcarbazepine Recall
American Health Packaging announced a voluntary recall of Ibuprofen Tablets 600mg and Oxcarbazepine Tables 300mg due to mislabeled inner unit dose blister packaging.
Fatty Acids May Prevent ALS
Amyotrophic lateral sclerosis (ALS) may be delayed or prevented with the consumption of foods high in ω-3 polyunsaturated fatty acids (PUFAs).
FEATURES
Numbness, Tingling, Weakness, and Coolness in a 'Jammed' Hand
A man tells the orthopedics clinic staff about odd sensations in his hand a week after a car accident.
Limbic_06.jpg&c=1&h=120&w=120 "Could Mild TBI Symptoms Be PTSD?")
Could Mild TBI Symptoms Be PTSD?
Persistent symptoms lasting three months after mild traumatic brain injury (mTBI) do not represent postconcussion syndrome (PCS) and should be considered part of the hyperarousal dimension of posttraumatic stress disorder.
Status Epilepticus Therapy Granted Fast Track Status
The FDA has designated Fast Track status to SAGE-547 (SAGE Therapeutics) for the treatment of adult patients with refractory status epilepticus who have not responded to standard regimens.
Featured courses from mycme
A 70-Year-Old Woman With Altered Cognition and Emotional Lability
Several illnesses may cause dementia, including dementia with Lewy bodies (DLB), Pick’s disease and other ...
MS: Focus on Neurodegeneration and Neuroprotection
This CME-certified roundtable discussion enables learners to strengthen their knowledge of the potential neuroprotective strategies ...
Re-examining the Role of Interferon in Treating Multiple Sclerosis
This CME/CE-certified activity focuses on the optimal management of multiple sclerosis with an emphasis on ...